Amnio Technology LLC

12 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Oct 2029

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 30, 2027
The maintenance fee for Frozen Therapeutic Dose and Package (US 10,363,278) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
1 fee due Mar 15, 2027
The maintenance fee for Acellular Amnion Derived Therapeutic Compositions (US 9,132,156) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
1 fee due Apr 3, 2027
The maintenance fee for Allograft Optimization System (US 11,772,200) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
1 fee due Jun 30, 2027
The maintenance fee for Amnion Derived Therapeutic Composition and Process of Making Same (US 10,517,903) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 11,207,355	Enriched Multilayer Amnion Derived Tissue Graft In force Term ends Oct 7, 2029 · Medium confidence	In force	Term ends Oct 7, 2029	Medium confidence
US 11,369,643	PROCESS OF MAKING An AMNION DERIVED THERAPEUTIC COMPOSITION In force Term ends Oct 7, 2029 · Medium confidence	In force	Term ends Oct 7, 2029	Medium confidence
US 12,433,917	Enriched Multilayer Amnion Derived Tissue Graft In force Term ends Oct 7, 2029 · Medium confidence	In force	Term ends Oct 7, 2029	Medium confidence
US 9,132,156	Acellular Amnion Derived Therapeutic Compositions In force Term ends Jan 9, 2035 · High confidence	In force	Term ends Jan 9, 2035	High confidence
US 9,814,746	Method of Treatment Utilizing an Acellular Amnion Derived Therapeutic Composition In force Ends no later than Jan 9, 2035 · Low confidence	In force	Ends no later than Jan 9, 2035	Low confidence
US 10,894,066	Amnion Derived Therapeutic Compositions and Methods of Use In force Ends no later than Jan 9, 2035 · Low confidence	In force	Ends no later than Jan 9, 2035	Low confidence
US 10,363,278	Frozen Therapeutic Dose and Package In force Ends no later than Jan 22, 2035 · Low confidence	In force	Ends no later than Jan 22, 2035	Low confidence
US 10,517,903	Amnion Derived Therapeutic Composition and Process of Making Same In force Ends no later than Sep 14, 2035 · Medium confidence	In force	Ends no later than Sep 14, 2035	Medium confidence
US 11,161,204	Allograft Optimization System In force Term ends Nov 18, 2040 · High confidence	In force	Term ends Nov 18, 2040	High confidence
US 11,772,200	Allograft Optimization System In force Term ends Jan 27, 2041 · High confidence	In force	Term ends Jan 27, 2041	High confidence

10 of 12 patents shown.

Pro members see all 12.

Pro members: see all 12 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned

List them